Treating Rare Endocrine Disorders with Therapeutic Peptides

Hypoparathyroidism is a rare condition that is caused by the lack of functional parathyroid glands. The condition can lead to a long list of complications including muscle pain, brain fog, and damage to the kidneys. Amolyt Pharma is developing a therapeutic peptide to treat hypoparathyroidism. We spoke to Mark Sumeray, chief medical officer of Amolyt, about what its like for people living with the condition, why it is difficult to manage with current medical approaches, and why therapeutic peptides offer a compelling approach for hypothyroidism and other endocrine disorders.